Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Leukemia, Myeloid, Acute 34Leukemia 32Myelodysplastic Syndromes 22Lymphoma, Follicular 18Lymphoma, Non-Hodgkin 16Lymphoma, B-Cell, Marginal Zone 16Lymphoma 16Lymphoma, Mantle-Cell 15Lymphoma, Large B-Cell, Diffuse 12Waldenstrom Macroglobulinemia 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Multiple Myeloma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Myelomonocytic, Chronic 9Burkitt Lymphoma 9Hematologic Neoplasms 8Recurrence 7Lymphoma, T-Cell, Peripheral 7Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Plasma Cell 7Lymphoma, Large-Cell, Anaplastic 6Leukemia, B-Cell 6Immunoblastic Lymphadenopathy 6Hodgkin Disease 6Sezary Syndrome 5Mycosis Fungoides 5Leukemia, Hairy Cell 5Intraocular Lymphoma 5Anemia 5

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × Lenalidomide × Other hematologic neoplasm × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡